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INTRODUCTION 
Definition 
Spectrum of infant infections 
Mechanism of infection 
 
	  	  	  	  	  I TRODUCTION 
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Perinatal infections 
§  Definition 
§  Bacterial or viral illnesses 
§  Passed from a mother to her baby 
§  Usually after rupture of membranes 
§  In utero 
§  During delivery process 
§  Mother, symptomatic or not during 
pregnancy   
	  	  	  	  	  I TRODUCTION 
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Congenital infections 
•  Growth retardation 
•  Congenital  
manifestations 










By contact, inhalation 
(with secretions, blood) 
Hematogenous  
Breast milk 
Person to person 
Umbilicus 
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Congenital infections 
•  Growth retardation 
•  Congenital 
manifestations 










Group B streptococci 
N.gonorrhoeae 
C.trachomatis 
 E.coli, Listeria, 
HSV,CMV, HIV, HBV 
Breast milk 
HIV, CMV, HBV  
Person to person  






Rubella, CMV, HIV,    
Toxoplasma gondii, 
Treponema pallidum, 
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Chlamydia trachomatis 
§  Most common bacterial sexually transmitted 
disease 
§  No obvious symptoms for majority of women 
§  Infection of mother 
 premature rupture of membranes and early labor 
 ophtalmia neonatorum (20-50%) 
     (within 1st month of life) 
à pneumonia  
(within 1 to 3 months of age) 
§  PCR  (cervix ok, eyes ?); IF; culture 
§  Screening during pregnancy  
§  No consensus 
PA  
8	  sbbc pmelin 20.10.2012 	  	  INTRODUCTION	   	  	  	  	  	  	  	  PATHOGENS              INTERVENTION                    GBS          CONCLUSION 
INTERVENTION 
Preconceptional / antenatal 
 or perinatal or postnatal 
INTE I  
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Components of an effective 
prevention program 
§  Understanding of biology and epidemiology 
§  Setting strategic priorities 
§  Identify « target » disease and « at risk » 
populations 
§  Conduct cost-effective analysis 
§  Burden of disease 
§  Incidence, morbidity, mortality, cost of providing care, losss 
of productivity 
§  Cost of preventive intervention 
§  Investing in material and human resources 
§  Provide adequate monitoring and evaluation 
INTE I  
Is there medical and societal cost-saving ? 
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Highly effective preventive measures 
§  Neonatal tetanus 
§  Maternal tetanus vaccination 
/ booster 
§  Neonatal ophtalmia  
§  Topical agents (not efficient against C.trachomatis) 
§  Silver nitrate, erythromycin, tetracycline, povidone 
iodine  
§  Hepatitis B 
§  Screening and vaccination 
§  HIV 
§  Anti-retroviral therapy 
INTE I  
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GROUP B STREPTOCOCCI 
Successful  practices in 
prevention 
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1887, Noccard-Mollereau, bovine mastitis 
1933, Group B Antigen  
1964, severe neonatal sepsis 
Ø 1970,	  N°1	  in	  neonatal	  infecCons	  
Gram positive cocci  
 Catalase - 
 β-hemolytic 
 CAMP test + 
 Hippurate + 
 Esculine- 
 Orange pigment 
	  
10 capsular serotypes (Ia, Ib, II-IX)  
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Group B streptococcal diseases in 
neonates 
§  Since the 1970s, leading cause of life-
threatening infections in newborns 
§  Neonatal illness/death 
§  Long-term disabilities 
§  Maternal morbidity  
§  Along pregnancy  
§  Peripartum 
§  Serious diseases among elderly and adults with 
underlying diseases 
§  Significant mortality 
GBS 
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80 % EOD	

EOD : 80-90 % occur  




GBS Neonatal Infections 	  
A. Schuchat, Clin Microb Rev 1998;11:497-513 
GBS 
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Burden of neonatal  GBS early onset 
diseases in European countries 




Spain 2 (1996) to 0.45 
(2008)  
Lopez Sastre et al. 
Acta Pediatr 2005 
Belgium 2 Melin, Indian J Med 
Res 2004 
Eastern Europe 0.2 - 4 Trijbels-Smeulders, 
Pediatr Infect Dis J 
2004 Western Europe 0.3 - 2 
The Netherlands  1.9 
Scandinavia 0.76 - 2 
Southern Europe 0.57 - 2 
Data assessing more accurately the true burden are needed 
 
-  Definition? 
-  Carriage rate ? 
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40 - 60 %!
2 - 4 %!
GBS EOD 
60 - 40 %!









GBS	  EOD	  verCcal	  transmission	  
GBS 
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GBS maternal colonization 
Risk factor for early-onset disease (EOD) : 
vaginal GBS colonization at delivery 
 
§  GBS carriers  
§  10 - 35 % of women 
§  Clinical signs not predictive 
§  Dynamic condition 
§  Intestinal reservoir 
§  Prenatal cultures late in pregnancy can predict 
delivery status 
GBS 
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Additional Risk Factors  
for Early-Onset GBS Disease 
  Obstetric factors:  
  Prolonged rupture of  
membranes,  
  Preterm delivery,  
  Intrapartum fever 
  GBS bacteriuria 
  Previous infant with GBS disease 
  Immunologic:  
  Low specific IgG to GBS capsular 
polysaccharide 
No difference in occurrence either in GBS 
Positive or Negative women, except 
intrapartum fever 
Lorquet S., Melin P. & al. 	
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GBS EOD - Belgian data 
§  Incidence 
§  1985 -1990: 3/1000 live births 
§  1999, estimation : 2/1000 live births 
§  2010, estimation : < 1/1000 live births  
§  Meningitis : 10 % 
§  Mortality : 5 -10 % 
§  60 % EOD (130 cases) : WITHOUT any maternal/
obstetric risk factor except colonization 
§  Prenatal screening 
§  Recto-vaginal cultures : 13-35 % GBS Positive 
P. Melin -  2001, 2007 - Reference laboratory for GBS.	

GBS 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 










-  C5a peptidase 
-  ….. Bacteria 
Peptidoglycan 
β-hemolysin, … 
IL1, IL6, TNF α, 
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GUIDELINES FOR PREVENTION 
OF GBS PERINATAL DISEASE 
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Which prevention 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 
different virulence factors (pili, scpB, …) 
 Intrapartum  antibioprophylaxis 
> 4 (2) hours before delivery 
GBS 
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Stages in the pathogenesis of GBS 
neonatal EOD : Bacterial & individual factors 
GBS  
pathogenesis 
Colonization : adhesion to epithelial cells 















« still expected » 
GBS 
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Prevention of perinatal GBS EOD	  
§  Intrapartum antibiotics 
§  Highly effective at 
preventing EOD in 
women at risk of 
transmitting GBS to 
their newborns ( > 4 h) 
(clinical trials in late 80s) 
Who is  
the women  
at risk ? 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases in 
the 1990s, U.S. 
   Consensus   
   guidelines: 
- Screening  
-Risk-based 
Group B Strep 
Association 
formed  
  1st ACOG & AAP 
   statements 
           CDC draft  
guidelines published 
S. Schrag, New Engl J Med 2000 
Schrag S. et al. N Engl J Med 2002; 347:233-9 
 
Screening >50%  
more effective  
than RF 
 
No effect on GBS LOD 
GBS 
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Why is Screening more protective 
than the risk-based approach ? 
Schrag	  S.	  et	  al.	  N	  Engl	  J	  Med	  2002;	  347:233-­‐9	  
Broader coverage of « at-risk » population 
Ø  Captures colonized women without obstetric RF 
Ø  High level of compliance with recommendations 
Ø  Enhanced compliance with risk-based approach 
cannot prevent as many cases as universal 
screening 
GBS 
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  Impact of prevention practices 
  Early- and Late-onset GBS Diseases, U.S. 
Incidence of early- and late-onset invasive group B streptococcal disease in 
















































   Consensus   
   guidelines: 
-   Screening-based 
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CDC, USA, MMWR, Vol 59 
(RR-10) August 2010 
Endorsed by 
  - AAP  
  - ACOG 
 
            SHC, Belgium July 2003 
Revision ongoing 
department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010
Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html
GBS 
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Universal screening-based strategy for 
prevention of GBS perinatal disease 
Vagino-rectal GBS screening culture  at 35-37 weeks of gestation  
 
For ALL pregnant women 
> 1 Risk factor:  
   - Intrapartum fever > 38°C*** 
   -  ROM > 18 hrs 




























if NO! if YES!
Unless patient had a previous infant with GBS invasive disease  
 or GBS bacteriuria during current pregnacy 
 or delivery occurs < 37 weeks’ gestation * 
GBS Neg 
if  YES!
GBS POS Not done, incomplete or 
unknown GBS result 
! Facultative !  
Intrapartum rapid GBS  test** 
GBS 
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By P.De Mol 
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Remaining burden of GBS EOD 
Missed opportunities 
In spite of universal screening prevention 
strategy 
In spite the great progress 
 Cases still occur 
§  Among remaining cases of EOD 
§  Some may be preventable cases 
§  Missed opportunities for (appropriate) IAP 
§  False negative screening 
Van Dyke MK, Phares CR, Lynfield R et al. N Engl J Med 2009 
CDC revised guidelines 2010 
Poyart C, Reglier-Poupet H, Tazi et al. Emerg Infect Dis 2008 
DEVANI project, unpublished data 2011 
 
GBS 
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SCREENING  
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Antenatal GBS culture-based 
screening 
Goal of GBS screening 
To predict GBS vaginal (rectal) colonization at the 
time of delivery 
§ 	  Critical factors influencing accuracy 
§  Swabbed anatomic sites 
§  Timing of sampling 




§  Non-culture  
GBS 
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From direct plating on blood agar 
Evolution of culture methods 	  
Use of selective enrichment broth 
§  To maximize the isolation of GBS 
§  To avoid overgrowth of other organisms 
 
Use of differential agar media 
Recommended by some European guidelines (+ CDC 2010) 
 
 1983, 1992                            2005       2007 
GRANADA 
(M.de la Rosa,JCM) 
Strepto B 
Select  
StreptoB ID  
Pigment-­‐based 	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chromogenic	  media	  
GBS 
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Which agar or which combination? 
+/- Blood agar 
 
Workload - costs - extra-testing - non β-hemolytic  
GBS detection  to be considered 
GBS 
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§  WHEN   35-37 weeks 
§  WHO  ALL the pregnant women 
§  Specimen   Vaginal + rectal swab(s) 
§  Collection  WITHOUT speculum 
§  Transport  Transport/collection device/condition 
 (non nutritive medium: Amies/Stuart   
 (type of swab)(Length and T°) 
§  Request form  To specify prenatal « GBS » 
 screening  
§  Laboratory procedure 
Crucial conditions to optimize 
SCREENING 
(CDC 2010 - Belgian SCH 2003) 
GBS 
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GBS 
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§  Use of a selective 
enrichment Lim broth 
 (BD, Copan, bioMérieux) 
 




§  Between 4-8°C  
Crucial conditions to optimize 
SCREENING 




§  At RT° up to 35°C  
 
           
§  Between 4-8°C  
Transport-collection system & transport-storage condition 
Preliminary results (2012, NRC GBS) 
GBS 
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§  Use of a selective 
enrichment Lim broth 
 (BD, Copan, bioMérieux) 
 
§  At RT° up to 35°C  
§  Rapid important amplification 
of GBS initial inoculum  
§  Sustained viability > 4 days  
§  Between 4-8°C  
§  > 24 hours, continuous  
decrease of life GBS 
Crucial conditions to optimize 
SCREENING 




§  At RT° up to 35°C  
§  Rapid important amplification 
of GBS initial inoculum  
§  Sustained viability at RT° 
§  Abrupt lost of viability at 35°C 
> 48-72h 
§  Between 4-8°C  
§  > 24 hours, continuous  
decrease of life GBS 
Transport-collection system & transport-storage condition 
Preliminary results (2012, NRC GBS) 
GBS 
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Prenatal culture-based 
screening: Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
§  Failure of GBS culture  (oral ATB, feminine hygiene, 
delay before culture) or new acquisition 
§  Up to 1/3 of GBS positive women at time of delivery 
§  Continuing occurrence of EO GBS cases 
§  False-positive  
§  Positive prenatal screening /negative at time of delivery 
§  Unnecessary IAP 
Need for more accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  colonizaCon	  
GBS 
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Prenatal culture-based 
screening: Limiting factors 
§  Positive and negative predictive values 
§  False-negative results 
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delay before culture) or new acquisition 
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§  False-positive  
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GBS 
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Prenatal culture-based screening 
combined with illumigene® Group B 
Streptococcus  assay 
A loop mediated isothermal amplification (LAMP) assay 
by Meridian Bioscience, Inc  
§  Broth enrichment followed by   
illumigene® GBS   
§  Speed and accuracy 
§  DNA detection 
GBS 
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Evaluation of the illumigene® GBS 






Overnight        at 35°C and 
subculture 
 







18 – 48h           at 35°C 
     ana            air 
illumigene  
GBS 
242 vagino-rectal swabs 
 
CHU Lg  
& AZ St-Lucas Gent 
illumigene GBS  
Pos/Neg/Invalid Enrichment  GBS  Pos (1-4+)/Neg Primary culture GBS  Pos (1-4+)/Neg 
GBS 
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Evaluation of the illumigene® GBS 
GBS Positive cultures:   20.7% 
illumigene GBS vs GBS reference culture (all discrepancies 
were retested) 
Sensitivity   90.0 % 
Specificity   98.9 % 
PPV    95.7 % 
NPV    97.4 % 
Efficiency   97.1 % 
  GBS culture  
  Positive Negative  
illumigene  
GBS 
Positive 45 2 47 
Negative 5 188 193 
  50 190 240 
GBS 
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Evaluation of the illumigene® GBS 
GBS Positive cultures:   20.7% 
illumigene GBS vs GBS reference culture /GBS DNA 
Sensitivity   90.0 %       95.7% 
Specificity   98.9 %       100% 
PPV    95.7 %       100 % 
NPV    97.4 %       99 % 
Efficiency   97.1 % 
  GBS culture  
  Positive Negative  
illumigene  
GBS 
Positive 45 2 : PCR pos 47 
Negative 2 positive        3 very rare GBS 188 193 
  50 190 240 
GBS 
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Evaluation of the illumigene® GBS 
§  Speed and accuracy 
§  Easy to perform, short hands-on-time 
§  Good comparison to reference culture 
method 
§  100% specificity and positive predictive 
value 
§  High sensitivity and negative predictive 
value 
§  Identification of >= 0.8% additional GBS 
positive specimen 
§  Overall cost and logistic to be considered  
GBS 
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Prenatal culture-based 
screening: Limiting factors 
§  Unknown GBS status at presentation for 
delivery 
§  Screening performed but result not available 
§  Women with no prenatal care 
Risk based strategy  
•  60% at GBS risk not identified 
•  > 10% of unnecessary IAP 
Need for rapid accurate	  predictor	  of	  	  
intrapartum	  GBS	  vaginal	  colonizaCon	  
GBS 
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Alternative to GBS prenatal 
screening: intrapartum screening 
Theranostic approach 
Turnaround time 








30-45 minutes, 24 hrs/7 d, robust 
Benitz et al. 1999, Pediatrics, Vol 183 (6) 
GBS 
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§  Inclusion of women without prenatal screening/care 
§  Identification of women with change of GBS status 
after 35-37 wks gestation 
§  Increased accuracy of vaginal GBS colonization 
status at time of labor & delivery 
 
Intrapartum screening theranostic 
approach: expected advantages 
IAP addressed to right target 
§  Reduction of inappropriate/unnecessary IAP 
§  Broader coverage of « at GBS risk women »  
Improvement of prevention  
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Real Time PCR for intrapartum 
screening 
§  Advance in PCR techniques & development of 
platforms 
§  BD GeneOhmTM Strep B Assay (+/- 1 hr) (in laboratory) 
§  Xpert GBS, Cepheid (35-45 min) (can be performed as a POCT)  
GBS 
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Real-­‐Cme	  PCR,	  very	  promising	  
§  Rapid, robust & accurate technology 
§  Still an expensive technology (specific equipment) 
§  Cost effective ?  
§  Need for more cost-effective clinical study 
§  Logistic 
§  24 hours 7 days 
§  In the lab? 
§  In the obstetrical department as a POCT ? 
§  In combination with prenatal screening strategy ? 
§  CDC 2010 : for women with premature delivery or no prenatal care 
§  No antimicrobial result  
§  In the future detection of R genes, but mixed microbiota ! 
GBS 
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VACCINE 
 
Prevention of GBS EOD and LOD 
	  
GBS 
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Vaccine - Background 
GBS 
§  Correlate between maternal low level off CPS 
type Ab at time of delivery and risk for 
development of GBS EOD  
Baker C et Kasper D, 1976, NEJM 
 
 Vaccine for pregnant women: 
 Likely the most effective, sustainable and cost 
effective approach 
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GBS Vaccines, since the 1980s   
Challenges 
GBS 
Capsular polysaccharide vaccines 
§  10 serotypes 
§  Different distributions 
§  EOD, LOD, invasives infections in adults 
§  Geographically and along time 
§  Conjugated vaccines 
§  Multivalent vaccines Ia, Ib, III, V 
§  Clinical studies 
§  Immunogenicity : ok 
§  Safety : ok 
§  Efficacy: scheduled/ongoing 
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GBS Vaccines 
GBS 
GBS Protein-based Vaccine 
§  Ag = Surface proteins 
§  Cross protection against different serotypes 
§  Better immunogenicity 
§  Humoral response T-cell dependent   
    = long lasting immunity 
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GBS Vaccines 
GBS « pilus like structure » 
GBS 
§  Highly immunogenic proteins 
§  Elicit protective and functional antibodies 
§  Virulence factor 
§  Adhesion 
§  Transcytose through cells 
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CONCLUSION 
Take home messages 
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GBS Summary 	  
§  EOD & LOD, a public health concern 
§  IAP, an effective prevention  
§  “Screening” Prevention strategies 
§  Improvement of culture-based GBS prenatal 
screening 
§  Culture-LAMP combined GBS prenatal 
screening   
§  Room for a rapid intrapartum screening (POCT) 
§  Development of a vaccine  
§  Against pili proteins and major capsular 
polysaccharidic serotypes 
	  	  	  	  	   LUSION 
